Colleen Kusy
Stock Analyst at Baird
(0.91)
# 3,750
Out of 4,877 analysts
47
Total ratings
29.27%
Success rate
-17.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Maintains: Outperform | $105 → $112 | $76.30 | +46.79% | 2 | Jun 25, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $20.08 | +158.96% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $4.57 | +31.29% | 4 | Jun 4, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $55 → $47 | $17.31 | +171.60% | 11 | May 8, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $19.22 | +113.32% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $0.73 | +720.46% | 5 | Dec 5, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $15.00 | +333.33% | 2 | Nov 13, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $4 → $3 | $0.30 | +913.51% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $9.28 | +83.19% | 4 | Aug 8, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $10.15 | +146.31% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $4.39 | +4,683.60% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.72 | +1,876.74% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $1.77 | +12,894.35% | 1 | Nov 2, 2021 |
Nuvalent
Jun 25, 2025
Maintains: Outperform
Price Target: $105 → $112
Current: $76.30
Upside: +46.79%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $20.08
Upside: +158.96%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $4.57
Upside: +31.29%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Outperform
Price Target: $55 → $47
Current: $17.31
Upside: +171.60%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $19.22
Upside: +113.32%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $0.73
Upside: +720.46%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $15.00
Upside: +333.33%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.30
Upside: +913.51%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $9.28
Upside: +83.19%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $10.15
Upside: +146.31%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $4.39
Upside: +4,683.60%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.72
Upside: +1,876.74%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $1.77
Upside: +12,894.35%